治疗嗜酸性粒细胞性哮喘的新型抗炎药-Benralizumab  

New type of anti-inflammatory drug for eosinophilic asthma—Benralizumab

作　　者：陆聪 闫荟羽[1] 柯巍[1] 张四喜[1] LU Cong;YAN Hui-yu;KE Wei;ZHANG Si-xi(Department of Pharmacy,the First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]吉林大学第一医院药学部

出　　处：《实用药物与临床》2019年第6期654-657,共4页Practical Pharmacy and Clinical Remedies

摘　　要：Benralizumab是美国食品药品管理局(FDA)最新批准的用于治疗12岁以上严重嗜酸性粒细胞性哮喘的抑制剂类抗炎药物,是一种可以直接与嗜酸性粒细胞白细胞介素(IL)-5受体结合的单克隆抗体,通过组织自然杀伤细胞诱导嗜酸性粒细胞的死亡,也是目前唯一可以在24 h内将嗜酸性粒细胞直接、快速和近乎完全清除的哮喘治疗用生物药物。Benralizumab耐受性良好,无严重不良反应,本文对其作用机制、药动学、剂量选择、临床研究、不良反应等进行综述。Benralizumab is an anti-inflammatory drug that is newly approved by the US Food and Drug Administration(FDA) for the treatment of severe eosinophilic asthma in patients over 12 years of age.It is a monoclonal antibody that can bind directly to the eosinophil interleukins-5(IL-5) receptor and induce the death of eosinophils by organizing natural killer cells.It is the only biological drug that can be used to treat eosinophils directly,quickly and almost completely in 24 hours at present.Benralizumab is well tolerated,and there are no reports of severe adverse reactions.The mechanism of action,pharmacokinetics,dose-selection,clinical study and adverse reactions of Benralizumab are reviewed here.

关 键 词：Benralizumab 嗜酸性粒细胞 哮喘 IL-5 单克隆抗体 

分 类 号：R974[医药卫生—药品]